The Role of the Gut Microbiome and Its Metabolites in Metabolic Diseases

Overview

Journal Protein Cell

Publisher Oxford University Press

Specialties Biochemistry
Cell Biology

Date 2020 Dec 21

PMID 33346905

Citations 148

Authors

Jiayu Wu

Kai Wang

Xuemei Wang

Yanli Pang

Changtao Jiang

Affiliations

Soon will be listed here.

Abstract

It is well known that an unhealthy lifestyle is a major risk factor for metabolic diseases, while in recent years, accumulating evidence has demonstrated that the gut microbiome and its metabolites also play a crucial role in the onset and development of many metabolic diseases, including obesity, type 2 diabetes, nonalcoholic fatty liver disease, cardiovascular disease and so on. Numerous microorganisms dwell in the gastrointestinal tract, which is a key interface for energy acquisition and can metabolize dietary nutrients into many bioactive substances, thus acting as a link between the gut microbiome and its host. The gut microbiome is shaped by host genetics, immune responses and dietary factors. The metabolic and immune potential of the gut microbiome determines its significance in host health and diseases. Therefore, targeting the gut microbiome and relevant metabolic pathways would be effective therapeutic treatments for many metabolic diseases in the near future. This review will summarize information about the role of the gut microbiome in organism metabolism and the relationship between gut microbiome-derived metabolites and the pathogenesis of many metabolic diseases. Furthermore, recent advances in improving metabolic diseases by regulating the gut microbiome will be discussed.

Citing Articles

RNA Modification in Metabolism.

Liu Y, Sun Z, Gui D, Zhao Y, Xu Y MedComm (2020). 2025; 6(3):e70135.

PMID: 40066222 PMC: 11892166. DOI: 10.1002/mco2.70135.

Impact of diet on the gut mycobiome of Hong Kong Chinese infants.

Fong J, Lok K, Yeung M, Li W, Woo P, Teng J Comput Struct Biotechnol J. 2025; 27:661-671.

PMID: 40061440 PMC: 11889518. DOI: 10.1016/j.csbj.2025.02.006.

Molecules-mediated bidirectional interactions between microbes and human cells.

Wu S, Bu X, Chen D, Wu X, Wu H, Caiyin Q NPJ Biofilms Microbiomes. 2025; 11(1):38.

PMID: 40038292 PMC: 11880406. DOI: 10.1038/s41522-025-00657-2.

Gut microbiota alterations induced by Roux-en-Y gastric bypass result in glucose-lowering by enhancing intestinal glucose excretion.

Ke Z, Lu Z, Li F, Zhao Q, Jiang X, Hu Z Gut Microbes. 2025; 17(1):2473519.

PMID: 40028693 PMC: 11881838. DOI: 10.1080/19490976.2025.2473519.

Association between dietary coenzyme Q10 intake and hyperuricemia in Chinese adults: a nationwide cross-sectional study.

Kuang H, Zhao D, Tian Z, Liu Z, Dai S, Zheng Y BMC Public Health. 2025; 25(1):806.

PMID: 40016661 PMC: 11869573. DOI: 10.1186/s12889-024-21041-3.

References

Fu T, Coulter S, Yoshihara E, Oh T, Fang S, Cayabyab F . FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019; 176(5):1098-1112.e18. PMC: 6701863. DOI: 10.1016/j.cell.2019.01.036. View

Bauer P, Duca F, Waise T, Rasmussen B, Abraham M, Dranse H . Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory Pathway. Cell Metab. 2017; 27(1):101-117.e5. DOI: 10.1016/j.cmet.2017.09.019. View

Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y . Association between Polycystic Ovary Syndrome and Gut Microbiota. PLoS One. 2016; 11(4):e0153196. PMC: 4836746. DOI: 10.1371/journal.pone.0153196. View

Norman R, Dewailly D, Legro R, Hickey T . Polycystic ovary syndrome. Lancet. 2007; 370(9588):685-97. DOI: 10.1016/S0140-6736(07)61345-2. View

Rubio L, Aranda-Olmedo I, Martin-Pedrosa M . Inclusion of Limited Amounts of Extruded Legumes Plus Cereal Mixes in Normocaloric or Obesogenic Diets for Rats: Effects on Lipid Profile. Foods. 2020; 9(6). PMC: 7353632. DOI: 10.3390/foods9060704. View

Lindheim L, Bashir M, Munzker J, Trummer C, Zachhuber V, Leber B . Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study. PLoS One. 2017; 12(1):e0168390. PMC: 5207627. DOI: 10.1371/journal.pone.0168390. View

Sun L, Pang Y, Wang X, Wu Q, Liu H, Liu B . Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta Pharm Sin B. 2019; 9(4):702-710. PMC: 6664038. DOI: 10.1016/j.apsb.2019.02.004. View

Matsubara T, Li F, Gonzalez F . FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2012; 368(1-2):17-29. PMC: 3491147. DOI: 10.1016/j.mce.2012.05.004. View

Enck K, Banks S, Yadav H, Welker M, Opara E . Development of a Novel Oral Delivery Vehicle for Probiotics. Curr Pharm Des. 2020; 26(26):3134-3140. PMC: 7992870. DOI: 10.2174/1381612826666200210111925. View

10.

Kelley S, Skarra D, Rivera A, Thackray V . The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome. PLoS One. 2016; 11(1):e0146509. PMC: 4701222. DOI: 10.1371/journal.pone.0146509. View

11.

Chang P, Hao L, Offermanns S, Medzhitov R . The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc Natl Acad Sci U S A. 2014; 111(6):2247-52. PMC: 3926023. DOI: 10.1073/pnas.1322269111. View

12.

Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

13.

Di Francesco A, Di Germanio C, Bernier M, de Cabo R . A time to fast. Science. 2018; 362(6416):770-775. PMC: 8504313. DOI: 10.1126/science.aau2095. View

14.

Shaw J, Zimmet P, de Courten M, Dowse G, Chitson P, Gareeboo H . Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?. Diabetes Care. 1999; 22(3):399-402. DOI: 10.2337/diacare.22.3.399. View

15.

Jandhyala S, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy D . Role of the normal gut microbiota. World J Gastroenterol. 2015; 21(29):8787-803. PMC: 4528021. DOI: 10.3748/wjg.v21.i29.8787. View

16.

Turnbaugh P, Ley R, Mahowald M, Magrini V, Mardis E, Gordon J . An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027-31. DOI: 10.1038/nature05414. View

17.

Da Silva H, Teterina A, Comelli E, Taibi A, Arendt B, Fischer S . Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018; 8(1):1466. PMC: 5780381. DOI: 10.1038/s41598-018-19753-9. View

18.

Reilly S, Saltiel A . Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017; 13(11):633-643. DOI: 10.1038/nrendo.2017.90. View

19.

Huang F, Zheng X, Ma X, Jiang R, Zhou W, Zhou S . Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism. Nat Commun. 2019; 10(1):4971. PMC: 6823360. DOI: 10.1038/s41467-019-12896-x. View

20.

Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L . Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep. 2016; 6:32002. PMC: 4994089. DOI: 10.1038/srep32002. View